Frankfurt - Delayed Quote EUR

Maravai LifeSciences Holdings, Inc. (MAR.F)

1.8100

+0.0100

+(0.56%)

As of 8:05:02 AM GMT+2. Market Open.

QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?

QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 14 days ago

MRVI
Is Maravai LifeSciences Holdings, Inc. (MRVI) the Top Stock to Buy According to 12 West Capital Management?

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other top stocks to buy according to 12 West Capital Management. Joel Ramin founded 12 West Capital Management in August 2011, […]

Insider Monkey 30 days ago

MRVI
Maravai Lifesciences price target lowered to $5 from $10 at Stifel

Stifel lowered the firm’s price target on Maravai Lifesciences (MRVI) to $5 from $10 and keeps a Buy rating on the shares. The firm notes Q4 revenues came up $1M light of the Street, while EBITDA fell short by $7M. As for the guide, management’s outlook is well below Street, but excludes all high volume CleanCap orders. Stifel believes the company is at point where the transition from COVID to non-COVID demand, the China uncertainty, and the opaqueness of key model area make for a low visibility

TipRanks last month

MRVI
Maravai LifeSciences (MRVI) Q4 2024 Earnings Call Transcript

MRVI earnings call for the period ending December 31, 2024.

Motley Fool last month

MRVI
Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

Schedules Conference Call for Thursday, March 20, 2025SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the

GlobeNewswire last month

MRVI
3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk

The stock market is in a bit of a tailspin of late as investors worry about the future of the economy. Three stocks that are down big this year but that investors should think twice about buying right now are SoundHound AI (NASDAQ: SOUN), Maravai LifeSciences (NASDAQ: MRVI), and Victoria's Secret (NYSE: VSCO). Voice artificial intelligence (AI) company SoundHound went from being a hot stock in 2024 to now being in a freefall.

Motley Fool last month

SOUNW

NVDA

MRVI
Maravai LifeSciences Holdings, Inc. (MRVI): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

We recently compiled a list of the 12 Cash-Rich Penny Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against the other cash-rich penny stocks. Shares priced under $5, commonly referred to as penny stocks, are a tempting bet for […]

Insider Monkey last month

MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against the other AI stocks. In a recent discussion at CNBC’s ‘Squawk on the Street’, NYU professor and AI expert, Gary […]

Insider Monkey last month

MRVI
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual repo

GlobeNewswire last month

MRVI
Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

SAN DIEGO, February 24, 2025--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced acquisition of Officinae Bio’s DNA and RNA business. This acquisition combines Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' leading drug substance manufacturing capabilities, providing customers comprehensive expertise and

Business Wire last month

MRVI
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

SAN DIEGO, February 04, 2025--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide g

Business Wire 2 months ago

MRVI
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

SAN DIEGO, February 03, 2025--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). This distribution p

Business Wire 2 months ago

MRVI

AVTR
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

SAN DIEGO, January 28, 2025--Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

Business Wire 2 months ago

MRVI
Three Top Undervalued Small Caps In US With Insider Buying

Over the last 7 days, the United States market has risen by 3.8%, contributing to a 24% climb over the past year, with earnings expected to grow by 15% annually. In such a dynamic environment, identifying stocks that are potentially undervalued and have insider buying can be key indicators of promising opportunities for investors seeking growth in small-cap companies.

Simply Wall St. 3 months ago

MRVI

SDHC

MTW
Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other stocks under $5 with biggest upside potential. On January 20, Bloomberg reported that relief swept through the markets as it became […]

Insider Monkey 3 months ago

MRVI
Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Announces Earnings Release DateSAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company al

GlobeNewswire 3 months ago

MRVI
Maravai Lifesciences initiated with a Neutral at Guggenheim

Guggenheim initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating as the firm expands its bioprocessing tools coverage. Maravai is a leading pure-play in mRNA capping and viral clearance assessment and while the current valuation likely limits downside, the firm’s Neutral view is based on its call that there are “more attractive categories within the bioprocessing subsegment.” Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T

TipRanks 4 months ago

MRVI
Exploring December 2024's Undervalued Small Caps With Insider Action In US

Over the last 7 days, the United States market has experienced a 4.0% drop, yet it remains up by 24% over the past year with anticipated earnings growth of 15% per annum in the coming years. In this dynamic environment, identifying promising small-cap stocks with insider activity can offer investors unique opportunities to capitalize on potential market inefficiencies.

Simply Wall St. 4 months ago

MRVI

ONEW

PMTS
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Carl Hull to Retire as Executive ChairmanSAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl H

GlobeNewswire 4 months ago

MRVI

BDX

FTRE
Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US

Over the last 7 days, the United States market has dropped by 1.2%, yet it has risen by an impressive 30% over the past year, with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying stocks that are perceived as undervalued and have insider buying can be a promising strategy for investors looking to capitalize on potential growth opportunities.

Simply Wall St. 5 months ago

ACNB

TLRY

MRVI

Performance Overview

Return	MAR.F	S&P 500 (^GSPC)
YTD	-63.80%	-6.75%
1-Year	-73.96%	+8.64%
3-Year	-94.14%	+27.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Maravai LifeSciences Holdings, Inc. (MAR.F)

QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?

Is Maravai LifeSciences Holdings, Inc. (MRVI) the Top Stock to Buy According to 12 West Capital Management?

Maravai Lifesciences price target lowered to $5 from $10 at Stifel

Maravai LifeSciences (MRVI) Q4 2024 Earnings Call Transcript

Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results

3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk

Maravai LifeSciences Holdings, Inc. (MRVI): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development

Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies

Three Top Undervalued Small Caps In US With Insider Buying

Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

Maravai Lifesciences initiated with a Neutral at Guggenheim

Exploring December 2024's Undervalued Small Caps With Insider Action In US

Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US

Performance Overview